Understanding Alveolar Rhabdomyosarcoma

Alveolar rhabdomyosarcoma (ARMS), also known as fusion-positive rhabdomyosarcoma, is a rare and aggressive form of cancer that mostly affects children and adolescents. It develops in soft tissues—often in areas like the arms, legs, or abdomen—and has a tendency to spread quickly to other parts of the body, such as the lymph nodes and bones.

​

Why It’s So Serious

​

ARMS is particularly dangerous because of how fast it grows and spreads. Many patients are diagnosed when the disease is already advanced. Although chemotherapy often works well at first—sometimes making the cancer undetectable within weeks—the majority of patients (about 94%) will face a relapse within a few months after treatment ends. At that point, treatment options are limited, and the disease is often considered incurable.
 

What Causes ARMS?
 

This cancer is caused by a genetic mutation, where two genes break apart and then fuse back together incorrectly. This genetic “mistake” drives the aggressive behavior of the cancer. There are only about 50 new cases of metastatic fusion-positive rhabdomyosarcoma diagnosed each year in the U.S., making it incredibly rare.
 

The Urgent Need for New Treatments
 

Despite decades of research, outcomes for high-risk ARMS patients have not significantly improved in over 30 years. This has led researchers and doctors to question the current “standard” treatment approach. Many believe the key to progress lies in understanding how the cancer becomes resistant to treatment, and how to stop it from coming back. Immunotherapy and other cutting-edge research hold promise, but more support is needed.

​

Together, We Can Create Change

​

While ARMS is a devastating diagnosis, there is hope. Foundations, researchers, families, and advocates around the world are working together to push for change—faster diagnoses, smarter treatments, and ultimately, cures. Every step forward brings us closer to a future where children diagnosed with this disease have real hope for survival.